CDMO Bespak has completed the renovation of its inhaler manufacturing facility at its Holmes Chapel, UK site.
Through this expansion, Bespak has both upgraded its existing facilities and constructed a new cGMP Grade D cleanroom environment.
The company has also installed a novel high-speed commercial aerosol mixing and filling line, boosting Bespak's manufacturing capacity for low global warming potential (GWP) pressurised metered dose inhalers (pMDIs).
This strategic move mirrors the industry's intent to improve the sustainability of pMDI manufacturing, as the industry standard — hydrofluorocarbons (HFCs) — have a high GWP.
According to Bespak, commercial production will commence around the end of Q1 of 2025.
Chief Operating Officer at Bespak, Darren Hodkinson, commented: “We are committed to leading the transition to low GWP propellants in pMDIs, and our expanded facilities will allow us to provide customers with an agile pathway to commercialisation at our Holmes Chapel site."
"The close collaboration with BES enabled a smooth and effective working relationship delivering certain phases ahead of schedule, enabling our site operations teams to start their preparation to go live on the line earlier than originally planned. Our customers will benefit from our drive to shorten timelines while maintaining excellence, facilitated in this case by our strong collaboration with BES.”